← SynDRA

VALRUBICIN

SynDRA canonical compound SYN0021757 — structure-anchored drug synonym record

All known targets

• TOP2A
• TOP2A; TOP2B

Mechanisms of action (all sources)

• DNA inhibitor
• topoisomerase inhibitor
• TOP2A INHIBITOR
• DNA topoisomerase II alpha inhibitor
• Inhibitor

Drug classes

• Antineoplastic Agents
• Enzyme Inhibitors
• Topoisomerase II Inhibitors
• Topoisomerase Inhibitors

ATC classes

• L01D · CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES

Cross-references

• PubChem CID: 454216
• ChEMBL: CHEMBL1096885
• DrugBank: DB00385
• ChEBI: CHEBI:135876
• KEGG: D02697
• RxNorm: 31435
• Wikipedia: Valrubicin
• TTD: D07IPB
• LINCS BRD: BRD-K72951360

Synonyms

• N-Trifluoroacetyladriamycin 14-valerate
• valstar
• N-Trifluoroacetyldoxorubicin 14-valerate
• AD-32
• Valrubicine
• Valrubicina
• NSC-246131
• Valstar
• Valstar preservative free
• Valrubicin [USAN]
• Valstar Preservative Free
• AD 32
• Antibiotic AD 32
• Valstar (TN)
• N-Trifluoroacetyladriamycin-14-valerate
• Trifluoroacetyladriamycin-14-valerate
• Valrubicin (USP/INN)
• Adriamycin, trifluoroacetyl-, 14-valerate
• [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate
• (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate
• (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester
• (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate
• Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester
• NSC 246131
• Valrubicin (AD-32)
• 2C6NUM6878
• Valtaxin
• 2-oxo-2-((2S,4S)-2,5,12-trihydroxy-4-(((2R,4S,5S,6S)-5-hydroxy-6-methyl-4-(2,2,2-trifluoroacetamido)tetrahydro-2H-pyran-2-yl)oxy)-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)ethyl pentanoate
• UNII-2C6NUM6878
• Valrubicin [USAN:USP:INN]
• AD32
• NSC246131
• HSDB 7288
• NCGC00164738-01
• VALRUBICIN [MI]
• VALRUBICIN [INN]
• VALRUBICIN [HSDB]
• VALRUBICIN [VANDF]

Reported adverse events

• Asthenia
• Cyst
• Cystitis
• Dizziness
• Dysuria
• Flatulence
• Headache
• Malaise
• Myalgia
• Nausea
• Nocturia
• Pruritus